1-benzyl-1,4-diazepane reduces the efflux of resistance-nodulation-cell division pumps inEscherichia coli

Anno: 2020

Autori: Casalone E., Vignolini T., Bracono L., Gardini L., Capitanio M., Pavone F.S., Dei S., Teodori E.

Affiliazione autori: Department of Biology, University of Florence, Via Madonna del Piano 6, 50019 Sesto Fiorentino, Italy; LENS – European Laboratory for Non-linear Spectroscopy, Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Via U. Schiff, 6 – 50019 Sesto Fiorentino, Italy; 4ational Institute of Optics–National Research Council, Largo Fermi 6, 50125 Florence, Italy; Department of Physics and Astronomy, University of Florence, Via Sansone 1, 50019 Sesto Fiorentino, Italy.

Abstract: Aim: To investigate the action mechanism of 1-benzyl-1,4-diazepane (1-BD) as efflux pump inhibitor (EPI) in Escherichia coli mutants: ΔacrAB or overexpressing AcrAB and AcrEF efflux pumps. Materials & methods: Effect of 1-BD on: antibiotic potentiation, by microdilution method; membrane functionality, by fluorimetric assays; ethidium bromide accumulation, by fluorometric real-time efflux assay; AcrB expression, by quantitative photoactivated localization microscopy. Results: 1-BD decreases the minimal inhibitory concentration of levofloxacin and other antibiotics and increase ethidium bromide accumulation in E. coli overexpressing efflux pumps but not in the ΔacrAB strain. 1-BD increases membranes permeability, without sensibly affecting inner membrane polarity and decreases acrAB transcription. Conclusion: 1-BD acts as an EPI in E. coli with a mixed mechanism, different from that of major reference EPIs.

Giornale/Rivista: FUTURE MICROBIOLOGY

Volume: 15 (11)      Da Pagina: 987  A: 999

Maggiori informazioni: This work was supported by Fondazione CR Firenze (grant numbers 2016.1086, 2017.0750, 2017.0827); the European Union´s Horizon 2020 research and innovation program grant no. 654148 Laserlab-Europe and by EMPIR project MetVBadBugs 15HLT01. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Parole chiavi: Multidrug resistance; MDR; E. coli; efflux-pump inhibitor; EPI; levofloxacin potentiation; membrane permeability; AcrAB expression
DOI: 10.2217/fmb-2019-0296

Citazioni: 5
dati da “WEB OF SCIENCE” (of Thomson Reuters) aggiornati al: 2024-06-16
Riferimenti tratti da Isi Web of Knowledge: (solo abbonati)
Link per visualizzare la scheda su IsiWeb: Clicca qui
Link per visualizzare la citazioni su IsiWeb: Clicca qui